Protek reported consolidated financial results for the first quarter of 2014. For the quarter, the company raised consolidated sales revenue 6.2% year-on-year in to RUB 36.826 billion. The retail segment saw the biggest revenue dynamic - 14.4%. A drop in the rate of growth for consolidated revenue was due to stronger price competition in the distribution segment and a drop in sales for AnviMaks and Antigrippin in the production segment. The company increased capital investment 50% year-on-year in 2013 to RUB 667 million. Capital investment in the distribution division grew 40% to RUB 242 million. Investment in retail jumped 60% to RUB 322 million and investment in distribution went up 30% to RUB 103 million. Capital investment in the retail division went mostly into organic development of the pharmacy chain.

The company reported that capital investment was planned at the same level as 2013 in 2014. The company plans significant investment in expanding production capacity in 2014. In the distribution segment, the company plans to invest in automating storage.